Cargando…
REV-ERB agonism improves liver pathology in a mouse model of NASH
Non-alcoholic fatty liver disease (NAFLD) affects a significant number of people worldwide and currently there are no pharmacological treatments. NAFLD often presents with obesity, insulin resistance, and in some cases cardiovascular diseases. There is a clear need for treatment options to alleviate...
Autores principales: | Griffett, Kristine, Bedia-Diaz, Gonzalo, Elgendy, Bahaa, Burris, Thomas P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529425/ https://www.ncbi.nlm.nih.gov/pubmed/33002003 http://dx.doi.org/10.1371/journal.pone.0236000 |
Ejemplares similares
-
REV-ERB activation as a novel pharmacological approach for treating inflammatory pain
por: Makhija, Sangeet, et al.
Publicado: (2023) -
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022) -
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
por: Griffett, Kristine, et al.
Publicado: (2023) -
Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB
por: Murray, Meghan H., et al.
Publicado: (2022) -
Direct Regulation of CLOCK Expression by REV-ERB
por: Crumbley, Christine, et al.
Publicado: (2011)